These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37158911)

  • 1. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
    Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J
    Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies.
    Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC
    J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability.
    Jha MK; Williamson DJ; Magharehabed G; Turkoz I; Daly EJ; Trivedi MH
    J Affect Disord; 2023 Jan; 321():153-160. PubMed ID: 36273682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
    Turkoz I; Nelson JC; Wilkinson ST; Borentain S; Macaluso M; Trivedi MH; Williamson D; Sheehan JJ; Salvadore G; Singh J; Daly E
    Psychiatry Res; 2023 May; 323():115165. PubMed ID: 37019044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
    Jamieson C; Canuso CM; Ionescu DF; Lane R; Qiu X; Rozjabek H; Molero P; Fu DJ
    Qual Life Res; 2023 Nov; 32(11):3053-3061. PubMed ID: 37439961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
    Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
    CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
    Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J
    CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
    Chen G; Chen L; Zhang Y; Li X; Lane R; Lim P; Daly EJ; Furey ML; Fedgchin M; Popova V; Singh JB; Drevets WC
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):269-279. PubMed ID: 35022754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
    Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
    CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.
    Desai U; Kirson NY; Guglielmo A; Le HH; Spittle T; Tseng-Tham J; Shawi M; Sheehan JJ
    J Comp Eff Res; 2021 Apr; 10(5):393-407. PubMed ID: 33565893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
    Fu DJ; Zhang Q; Shi L; Borentain S; Guo S; Mathews M; Anjo J; Nash AI; O'Hara M; Canuso CM
    BMC Psychiatry; 2023 Aug; 23(1):587. PubMed ID: 37568081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.
    Turkoz I; Alphs L; Singh J; Jamieson C; Daly E; Shawi M; Sheehan JJ; Trivedi MH; Rush AJ
    Acta Psychiatr Scand; 2021 Mar; 143(3):253-263. PubMed ID: 33249552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.